Trading
Bayer Shares up After First Trial Win Over Roundup
Published by maria gbaf
Posted on October 6, 2021
1 min readLast updated: January 31, 2026
Add as preferred source on Google
Global Banking & Finance Review®
Company
Published by maria gbaf
Posted on October 6, 2021
1 min readLast updated: January 31, 2026
Add as preferred source on GoogleBayer's shares increased by 2.5% after a jury ruled in favor of the company in a Roundup cancer trial, marking Bayer's first legal victory in such cases.
BERLIN (Reuters) – Shares in Bayer AG rose 2.5% in pre-market trade on Wednesday after the German agricultural and pharmaceuticals firm won its first trial over claims its Roundup weedkiller causes cancer.
A California jury found that the herbicide was not a substantial cause of a child’s rare form of non-Hodgkin’s lymphoma, the company said on Tuesday. The verdict is the fourth involving Roundup and the first in the company’s favor.
Roundup-related lawsuits have dogged Bayer since it acquired the brand as part of its $63 billion purchase of agricultural seeds and pesticides maker Monsanto in 2018.
(Reporting by Emma Thomasson; Editing by Muralikumar Anantharaman)
The article discusses Bayer's share increase following a legal victory in a Roundup cancer trial.
The trial was about claims that Bayer's Roundup weedkiller causes cancer.
A California jury ruled that Roundup was not a substantial cause of a child's cancer.
Explore more articles in the Trading category
